Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,450,000 shares, a growth of 14.2% from the October 15th total of 1,270,000 shares. Currently, 3.2% of the shares of the stock are short sold. Based on an average daily volume of 184,900 shares, the short-interest ratio is currently 7.8 days.
Hedge Funds Weigh In On Acumen Pharmaceuticals
A number of large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD bought a new stake in Acumen Pharmaceuticals in the first quarter worth about $4,449,000. Renaissance Technologies LLC purchased a new stake in shares of Acumen Pharmaceuticals in the second quarter worth approximately $818,000. Bank of New York Mellon Corp bought a new stake in shares of Acumen Pharmaceuticals during the 2nd quarter worth approximately $306,000. State Street Corp boosted its holdings in Acumen Pharmaceuticals by 18.3% during the 3rd quarter. State Street Corp now owns 516,406 shares of the company’s stock valued at $1,281,000 after acquiring an additional 79,841 shares during the period. Finally, Murchinson Ltd. purchased a new position in Acumen Pharmaceuticals during the 2nd quarter valued at $136,000. 71.01% of the stock is owned by hedge funds and other institutional investors.
Acumen Pharmaceuticals Price Performance
NASDAQ:ABOS opened at $2.40 on Monday. The firm has a market capitalization of $144.19 million, a price-to-earnings ratio of -1.74 and a beta of 0.04. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 17.37. The business has a 50 day simple moving average of $2.62 and a 200-day simple moving average of $2.79. Acumen Pharmaceuticals has a 1 year low of $2.08 and a 1 year high of $5.09.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on ABOS shares. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Acumen Pharmaceuticals in a research note on Wednesday, November 13th. UBS Group lowered their target price on Acumen Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Finally, Citigroup upgraded shares of Acumen Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th.
View Our Latest Stock Report on ABOS
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.
Read More
- Five stocks we like better than Acumen Pharmaceuticals
- Stock Sentiment Analysis: How it Works
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- There Are Different Types of Stock To Invest In
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- The Significance of Brokerage Rankings in Stock Selection
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.